| ²é¿´: 401 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÐÂÈËÇóÖú·Òë
|
||
|
1For example, VEGF receptor TKIs are effective as monotherapy in certain cancers, but fail in others or are toxic when combined with chemotherapy. 2 Many patients with metastatic disease are refractory or acquire resistance to VEGF inhibitors, and biomarkers to identify responders are missing. 3 VEGF and Notch co-operate in an integrated intercellular feedback that functions as a ¡®¡®branching pattern generator¡¯¡¯ . VEGF stimulates tip cell induction and filopodia forma-tion via VEGF receptor-2 (VEGFR2), whereas VEGFR2 blockade causes sprouting defects with blunt-ending channels . VEGFR3 is expressed in the embryonic vasculature but later becomes confined to lymphatics. |
» ²ÂÄãϲ»¶
334Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
085600²ÄÁÏÓ뻯¹¤×¨Ë¶329 Çóµ÷¼Á
ÒѾÓÐ21È˻ظ´
320·ÖÈ˹¤ÖÇÄܵ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸»ª¶«Àí¹¤085601²ÄÁϹ¤³Ì303·ÖÇóµ÷¼Á
ÒѾÓÐ15È˻ظ´
²ÄÁϹ¤³Ì085601£¬270Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
290Çóµ÷¼Á085701
ÒѾÓÐ17È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ4È˻ظ´
0703µ÷¼Á£¬Ò»Ö¾Ô¸Ìì½ò´óѧ319·Ö
ÒѾÓÐ26È˻ظ´
Ò»Ö¾Ô¸Äϲý´óѧ£¬085600£¬344·ÖÇóµ÷¼Á
ÒѾÓÐ12È˻ظ´
ÍÁľˮÀûר˶276·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´

ÀîÊÏÊÏ
½û³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 45
- Ó¦Öú: 79 (³õÖÐÉú)
- ½ð±Ò: 1468.3
- É¢½ð: 3
- ºì»¨: 3
- Ìû×Ó: 417
- ÔÚÏß: 161.3Сʱ
- ³æºÅ: 2207530
- ×¢²á: 2012-12-26
- רҵ: »á¼ÆÓëÉó¼Æ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
phu_grassman: ½ð±Ò+3, thanks 2013-03-01 09:05:12
yin198716: ½ð±Ò+5, ·ÒëEPI+1 2013-03-01 10:30:54
phu_grassman: ½ð±Ò+3, thanks 2013-03-01 09:05:12
yin198716: ½ð±Ò+5, ·ÒëEPI+1 2013-03-01 10:30:54
|
1. ÀýÈç±íƤÉú³¤Òò×ÓÊÜÌåÀÒ°±ËἤøÒÖÖÆ¼Á×÷Ϊµ¥Ò©ÖÎÁƶÔÄ³Ð©ÌØ¶¨µÄ°©Ö¢ÊǺÜÓÐЧµÄ¡£µ«ÊǶÔÓÚÆäËû°©Ö¢È´²¢ÎÞÁÆÐ§£¬Ó뻯ÁƽáºÏ»¹»á²úÉú¶¾ÐÔ¡£ 2. ¶ÔÓÚÐí¶àÓÐ×ªÒÆÐÔ¼²²¡µÄ»¼ÕßÀ´Ëµ£¬ÊǺÜÄÑÖÎÓúµÄ£¬ »òÕß¶ÔѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓÒÖÖÆ¼Á²úÉúµÖ¿¹£¬ÉúÎïÖ¸±êÎïʶÏìÓ¦²»Ã÷ÏÔ¡£ 3. VEGFÓëNotch×÷Ϊ¡°·Ö֧ģʽÉú³ÉÆ÷¡±µÄ¹¦ÄÜÔÚϸ°û¼äÏ໥×÷Óá£VEGFͨ¹ýѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓÊÜÌå2£¨VEGFR2£©´Ì¼¤¸ù¼âϸ°ûÓÕµ¼ºÍ˿״α×ãµÄÐγɣ¬VEGFR2·âËøÓë¶Û½áÊøÍ¨µÀ×èÖ¹ÔÙÉú¡£ÔÚÅß̥Ѫ¹ÜVEGFR3½øÐд«µÝ£¬µ«Ö®ºó½öÏÞÓÚÁܰ͹ÜÄÚ¡£ |
2Â¥2013-01-23 10:01:22














»Ø¸´´ËÂ¥